Trials / Completed
CompletedNCT00674739
Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center, Efficacy and Safety Study of Imiquimod Creams in the Treatment of External Genital Warts
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 470 (actual)
- Sponsor
- Graceway Pharmaceuticals, LLC · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether imiquimod creams are effective in treating external genital warts (EGW). The secondary objective of this study is to provide information on recurrence of EGW. Additionally the study will also look at any adverse events associated with the use of the creams. External genital and perianal warts are caused by the infection of human papillomavirus or HPV. HPV infection is a sexually transmitted disease (STD). External genital warts look like small flesh-colored, pink, or red growths on or around the external skin of sex organs or perianal area. The warts may look similar to the small parts of a cauliflower or they may be very tiny and difficult to see. They often appear in clusters of three or four, and may grow and spread rapidly. They usually are not painful, although they may cause mild pain, bleeding, and itching.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imiquimod | daily topical application for up to 8 weeks |
| DRUG | 3.75% imiquimod cream | 3.75% imiquimod cream applied daily to wart areas for up to 8 weeks. |
| DRUG | placebo cream | placebo cream applied daily to wart areas for up to 8 weeks |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2008-05-08
- Last updated
- 2011-05-24
- Results posted
- 2011-05-18
Locations
30 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00674739. Inclusion in this directory is not an endorsement.